fda semaglutide shortage status january 2025 Federal judge upholds FDA's removal of Ozempic, Wegovy from drug list Ozempic, Wegovy shortages are resolved

The percentage of patients who discontinued due to ineffective therapy was 5.4% in the liraglutide injection 1.8 mg + metformin treatment group, 3.3% in the liraglutide injection 1.2 mg + metformin treatment group, 23.8% in the placebo + metformin treatment group, and 3.7% in the glimepiride + metformin treated group

Effects of Bitter Substances on GI Function, Energy Intake and Glycaemia-Do Preclinical Findings Translate to Outcomes in Humans

Stacking GLP-1 agonists increases the risk of severe gastrointestinal events and hypoglycemia without proportional benefits

Chemical properties and biological activity of bee pollen